Belung Magazine -Belung Magazine
This site uses cookies to improve your browsing experience. By using this site, you agree to their use OK, I agree No, give me more info




BELUNG is an international, online magazine that aims to appear several times a year. It's focused on interstitial lung diseases (ILD), a group of lung diseases that affect the tissue and space around the air sacs of the lungs, the so called interstitium.

For whom is BELUNG?

BELUNG is for everyone! With BELUNG we want to reach people all across the spectrum. From people that don't know much about ILD, to world leading experts. We strongly believe that by connecting people from different fields, we can do a lot for ILD-patients. All these people can share their experiences about ILD with each other and enlarge each other's knowledge. In short, BELUNG is essential reading for everyone with a personal, professional or other kind of interest in ILD.


While there is a lot of knowledge about other lung diseases (like COPD or asthma), there's not much information to be found on ILD and therefore the awareness of ILD is very low. It can be very beneficial for ILD-patients to create knowledge about their condition. BELUNG aims to create awareness by educating people about a disease that is still a 'big unknown' for so many patients that receive the diagnosis.

What can I read about in BELUNG?

Every new edition will be filled with interviews with people who are in some way involved in ILD. From patients and healthcare professionals to patient organizations, governments and family members. Everybody who is involved in ILD is invited to contribute, as sharing information and experiences about the condition is one of the most important objectives of BELUNG. Each issue will also contain articles in which scientific concepts are explained, research findings and comments on the latest news from the world of ILD.

BELUNG Magazine is an initiative of Boehringer Ingelheim, a pharmaceutical company that is actively pursuing knowledge on the cause of interstitial lung diseases that can ultimately be used to develop new treatment options for patients that are affected by this group of diseases.